SG11201901830UA - nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS - Google Patents
nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODSInfo
- Publication number
- SG11201901830UA SG11201901830UA SG11201901830UA SG11201901830UA SG11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA SG 11201901830U A SG11201901830U A SG 11201901830UA
- Authority
- SG
- Singapore
- Prior art keywords
- utah
- nnif
- international
- suite
- salt lake
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383243P | 2016-09-02 | 2016-09-02 | |
| US201762492019P | 2017-04-28 | 2017-04-28 | |
| PCT/US2017/050072 WO2018045371A2 (en) | 2016-09-02 | 2017-09-05 | nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901830UA true SG11201901830UA (en) | 2019-03-28 |
Family
ID=61309026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901830UA SG11201901830UA (en) | 2016-09-02 | 2017-09-05 | nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10857201B2 (de) |
| EP (1) | EP3506924A4 (de) |
| JP (1) | JP2019534247A (de) |
| KR (1) | KR20190045271A (de) |
| CN (1) | CN109937047A (de) |
| AU (1) | AU2017321965A1 (de) |
| BR (1) | BR112019004299A2 (de) |
| CA (1) | CA3035770A1 (de) |
| MX (1) | MX2019002479A (de) |
| RU (1) | RU2019109049A (de) |
| SG (1) | SG11201901830UA (de) |
| WO (1) | WO2018045371A2 (de) |
| ZA (1) | ZA201901942B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11324801B2 (en) | 2016-09-02 | 2022-05-10 | University Of Utah Research Foundation | NNIF and nNIF-related peptides and related methods |
| EP4146237A1 (de) * | 2020-05-04 | 2023-03-15 | University of Utah | Immunthrombose bei covid-19-akust-respiratorischem stresssyndrom |
| CN117004744B (zh) * | 2022-04-27 | 2024-05-24 | 数字碱基(南京)科技有限公司 | 一种基于血浆微生物dna特征的肺癌预后评估方法及模型 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7799766B2 (en) * | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| US9308235B2 (en) * | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| EP4219534A3 (de) * | 2013-07-08 | 2023-09-27 | The University of Utah Research Foundation | Verfahren zur behandlung von und vorbeugung gegen entzündliche erkrankungen |
-
2017
- 2017-09-05 EP EP17847679.2A patent/EP3506924A4/de active Pending
- 2017-09-05 RU RU2019109049A patent/RU2019109049A/ru unknown
- 2017-09-05 WO PCT/US2017/050072 patent/WO2018045371A2/en unknown
- 2017-09-05 BR BR112019004299A patent/BR112019004299A2/pt unknown
- 2017-09-05 AU AU2017321965A patent/AU2017321965A1/en not_active Abandoned
- 2017-09-05 JP JP2019512681A patent/JP2019534247A/ja active Pending
- 2017-09-05 KR KR1020197009122A patent/KR20190045271A/ko not_active Application Discontinuation
- 2017-09-05 CN CN201780067221.2A patent/CN109937047A/zh active Pending
- 2017-09-05 US US16/328,697 patent/US10857201B2/en active Active
- 2017-09-05 CA CA3035770A patent/CA3035770A1/en active Pending
- 2017-09-05 SG SG11201901830UA patent/SG11201901830UA/en unknown
- 2017-09-05 MX MX2019002479A patent/MX2019002479A/es unknown
-
2019
- 2019-03-28 ZA ZA2019/01942A patent/ZA201901942B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109937047A (zh) | 2019-06-25 |
| RU2019109049A3 (de) | 2020-12-24 |
| US10857201B2 (en) | 2020-12-08 |
| EP3506924A4 (de) | 2020-05-20 |
| EP3506924A2 (de) | 2019-07-10 |
| MX2019002479A (es) | 2019-09-19 |
| US20190201487A1 (en) | 2019-07-04 |
| WO2018045371A2 (en) | 2018-03-08 |
| WO2018045371A3 (en) | 2018-04-12 |
| RU2019109049A (ru) | 2020-10-05 |
| CA3035770A1 (en) | 2018-03-08 |
| BR112019004299A2 (pt) | 2019-05-28 |
| JP2019534247A (ja) | 2019-11-28 |
| AU2017321965A1 (en) | 2019-04-04 |
| KR20190045271A (ko) | 2019-05-02 |
| ZA201901942B (en) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201910019PA (en) | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201906373VA (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201810443SA (en) | Invasive medical devices including magnetic region and systems and methods | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201408261UA (en) | Syringe | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201900442PA (en) | Sorting of t lymphocytes in a microfluidic device | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201903889TA (en) | Crenolanib for treating flt3 mutated proliferative disorders associated mutations | |
| SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201903786UA (en) | Farnesyltransferase inhibitors for use in methods of treating cancer | |
| SG11201909501TA (en) | Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro | |
| SG11201408171SA (en) | Fbxo3 inhibitors | |
| SG11201901673SA (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers | |
| SG11201908275XA (en) | Peptides and methods for the treatment of diabetes |